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IN PRACTICE
An analysis of the global burden of tuberculosis (TB) during pregnancy 
estimated that each year, more than 8 400 pregnant women in South 
Africa (SA) have active TB.[1] To put this burden into context, across 
sub-Saharan Africa, the combination of TB and HIV in pregnancy is 
a leading cause of maternal mortality[2] and in SA an estimated 65% of 
TB patients are HIV-positive. SA also ranks among the top countries 
in the world in terms of the number of TB patients with rifampicin-
resistant TB (RR-TB),[3] including multidrug-resistant (MDR) TB and 
extensively drug-resistant (XDR) TB. RR-TB requires 18 - 24 months of 
complex treatment with a high frequency of adverse drug reactions and 
poor treatment outcomes. Globally less than 50% of the 2011 cohort of 
MDR-TB patients were treated successfully.[3] 
Globally, there is scant evidence on the safety of second-line TB 
medications during pregnancy. Clinicians rely on data extrapolated 
from decades-old clinical trials[4] or from limited case series.[5] 
Clinicians must weigh the scant safety data against evidence that 
delayed RR-TB treatment may increase the risk of obstetric and 
neonatal complications from TB disease,[6] ongoing transmission, 
and that suboptimal RR-TB treatment can lead to failure and the 
amplification of resistance. 
Estimating the burden of pregnancy 
during RR-TB treatment in SA
In order to quantify the risk of pregnancy and RR-TB treatment, 
we analysed the drug-resistant TB case registry in SA to assess the 
number of women receiving RR-TB during their reproductive years. 
Setting and treatment guidelines
SA RR-TB patients receive a standardised regimen: 6 months of an 
injectable drug (kanamycin or amikacin) and 18 - 24 months of 
moxifloxacin, ethionamide, terizidone and pyrazinamide. Patients 
with second-line drug resistance, toxicity, or contraindications to the 
standardised regimen can access individualised regimens including 
capreomycin, para-aminosalicylic  acid, clofazimine, linezolid and 
bedaquiline. SA has universal testing for rifampicin resistance with 
public sector coverage of Xpert MTB/RIF since the end of 2013. 
Data extraction and analysis
The Electronic DR-TB Register (EDRweb) is the RR-TB national case 
register and, since 2012, has been used for reporting to the World Health 
Organization (WHO). A census of patients registered in the EDRweb 
from January 2009 to December 2014 was exported (N=53 623). 
Registrations missing sex, report of rifampicin resistance or date of 
treatment initiation details were excluded. Pregnancy and pregnancy 
outcomes are not routinely reported in the EDRweb.
Descriptive counts and proportions for gender, age category 
(0 - 14, 15 - 29, 30 - 44, 45 - 59, 60+), HIV status (negative, positive 
or unknown), history of prior TB treatment with any outcomes, 
and category of drug resistance (RR-TB and MDR-TB or second-
line drug resistance as indicated by XDR-TB case registration) are 
presented. Differences of proportions were estimated using Pearson’s 
χ2 and p-values are presented. All analyses were conducted in Stata SE 
version 13 (College Station, USA). 
Ethical approval
The University of the Witwatersrand Human Research Ethics 
Committee approved this retrospective, de-identified, secondary 
analysis in April 2015.
Results
From 2009 to 2014, 49 680 patients with RR-TB were registered 
and initiated on second-line TB treatment in the EDRweb. Nearly 
half (47.2%, n=23 428) were female. Males had a median age of 37 
(interquartile range (IQR) 30 - 45) years and females a median age 
of 32 (IQR 26 - 40) years. Eighty percent (n=18 750) of the women 
treated for RR-TB were aged 15 - 44 years. 
At initiation of RR-TB treatment (Table 1), women were younger 
(40.0% v. 24.9% aged <30), more likely to be HIV-infected (68.0% v. 
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IN PRACTICE
57.2%), less likely to have a history of TB 
treatment prior to their RR-TB diagnosis 
(60.8% v. 65.7%), and more likely to have 
XDR-TB (6.9% v. 6.2%) than men. Women 
aged 15 - 44 years were more likely to be HIV-
positive than women <15 years or >44 years 
(70.8% v. 53.9%, p<0.000).
An urgent call to action 
From 2009 to 2014, 23 428 women initiated 
RR-TB treatment in SA. Of these women 
on second-line TB treatment, 80% were of 
reproductive age. In contrast, a 2012 review 
of TB treatment in pregnant and postpartum 
women found only eight published case 
reports to guide second-line TB treatment 
during pregnancy, describing outcomes for 
73 women.[5] Most (68.0%) of the women 
treated for RR-TB in SA are also HIV-positive, 
yet the case reports describe outcomes for just 
six HIV-positive women.[5]
These numbers should serve as an urgent 
call to action:
1.  Collect more evidence of the safety 
of second-line TB treatment during 
pregnancy
Mothers with RR-TB and their clinicians are 
faced with a difficult decision. Should they 
treat the mother’s RR-TB and expose the 
fetus to potentially toxic drugs, or delay or 
stop treatment and face the risk of maternal 
or fetal mortality or the amplification of 
drug resistance? The principal concern is 
ototoxicity related to the injectable drugs, 
among the mainstays of second-line TB 
treatment. More evidence of the safety of 
second-line TB treatment during pregnancy 
is urgently needed to inform these decisions. 
This is a broader call than adverse drug event 
monitoring given the importance of also 
reporting the outcomes of TB and pregnancy 
even in the absence of adverse drug events. 
Monitoring RR-TB and pregnancy outcomes 
requires co-ordination across different 
facilities and health directorates, as women 
need to be identified during antenatal care 
and followed through delivery and post-
partum. The drugs-exposure pregnancy 
register led by the WHO can serve as a 
model of a feasible system for resource-
limited contexts.[7] 
2.  Ensure access to effective contraception 
during second-line TB treatment
Currently, contraception services in SA are 
offered at primary healthcare level while 
RR-TB services are more centralised, often 
still at hospital level. Offering effective 
contraception to women on second-line 
TB treatment could reduce the number of 
pregnancies during active TB. Integration of 
family planning services within the RR-TB 
units is therefore urgently needed. 
3.  Ensure women’s health is included in 
research on prevention and treatment of 
TB
Effective TB research is the third pillar of 
the WHO strategy to end TB. This research 
must address women’s health, especially 
reproductive health. More information and 
evidence on effective TB prophylaxis for 
women and infants, pharmacokinetics of TB 
drugs in pregnancy and pharmacokinetics 
of contraceptives and antiretrovirals during 
TB treatment is needed urgently.[8] 
Conclusion
In SA, where the burden of RR-TB and TB/
HIV co-infection is high, there is an urgent 
need for increased evidence of the safety of 
RR-TB treatment during pregnancy. Increased 
access to contraception during RR-TB 
treatment and inclusion of reproductive 
health in research on the prevention and 
treatment of TB need to be addressed. 
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Table 1. Differences in baseline characteristics of RR-TB patients registered in the 
EDRweb, 2009 - 2014, by sex
Female, n (%) Male, n (%) Total, n (%) p-value
All RR-TB 23 428 (47.2) 26 242 (52.8) 49 680 (100)
Age (years) <0.000*
0 - 14 768 (3.3) 584 (2.2) 1 352 (2.7)
15 - 29 8 597 (36.7) 5 994 (22.7) 14 541 (29.3)
30 - 44 10 153 (43.3) 12 575 (47.9) 22 728 (45.7)
45 - 59 3 233 (13.8) 6 107 (23.3) 9 340 (18.8)
≥60 687 (2.9) 1 032 (3.9) 1 719 (3.5)
HIV infection <0.000
HIV-negative 5 288 (22.6) 8 389 (32.0) 13 677 (27.5)
HIV-positive 15 936 (68.0) 15 011 (57.2) 30 947 (62.3)
HIV unknown 2 214 (9.4) 2 842 (10.8) 5 056 (10.2)
Previous TB <0.000
No prior TB 9 158 (39.2) 8 966 (34.3) 18 124 (36.6)
History of TB 14 191 (60.8) 17 187 (65.7) 31 378 (63.4)
Drug resistance <0.001
RR- or MDR-TB 21 816 (93.1) 24 614 (93.8) 46 430 (93.5)
XDR-TB 1 622 (6.9) 1 628 (6.2) 3 250 (6.5)
*p-values estimated using χ2 difference of proportions.
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